Background Tofacitinib is a novel oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). There was a study concerned with the efficacy for inhibiting the progression of radiographic joint damage (RJD) by tafacitinive (1). However, there has been no study to investigate inhibitory effects of small (hand and feet), medium and large (M-L) sized joints by tofacitinive. Here we report the tofacitinib efficacy of response up to 48 months with mono-therapy in long-term extension studies.

Objectives To analyze inhibitory effects of RJD progression in small joints (12 and 48 months) and M-L sized joints (48 months) treated with tofacinitib mono-therapy.

Methods The modified total sharp score (mTSS) was assessed to find small joint destruction. Twelve M-L sized joints (bilateral elbow, shoulder, hip, knee, ankle, and subtalar joints) were radiographically assessed by the Larsen method (Grade 0–5). Wilcoxon test was used for the statistical analysis.

Results Data were shown in Table. ΔmTSS/year after tafacitinive treatment was significantly decreased from 22.1 (baseline) to 3.93 (median:1) (after 1 year) (p<0.01), and 3.03 (median:1.8) (after 4 year) (p<0.01). Only one patient with severe MRI osteitis in hand progressed joint destruction resistant to the therapy. Mean Larsen score of M-L joints from baseline (1.29) to the last observation (1.31) did not have significant changed. Atlant-axial subluxation occurred in 4 patients did not progress during tofacitinive therapy.

• Download figure
• Open in new tab
• Download powerpoint

Conclusions Progression of small and M-L sized joints were effectively inhibited by tofacitinive mono-therapy.

References

1. Désirée van der Heijde et al. Arthritis Rheum 2003;65:559-570

Disclosure of Interest : None declared

DOI 10.1136/annrheumdis-2014-eular.5385